SEC Filing Analysis: Daré Bioscience, Inc. (DARE)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: Daré Bioscience received a Nasdaq deficiency notification on September 28, 2026, for failing to maintain the $1.00 minimum bid price requirement, with an initial compliance window through March 29, 2027.
• Market Impact: Neutral to slightly negative near-term sentiment driven by delisting overhang and prospective reverse stock split risk.

Company Information

Field	Value
Company	Daré Bioscience, Inc.
Ticker Symbol	DARE
CIK	0001401914
Industry	Pharmaceutical Preparations [2834]
Exchange	The Nasdaq Capital Market

Event Overview

Field	Value
Form Type	8-K
Report Date	September 28, 2026
Filing Date	October 2, 2026
Item Disclosed	Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule)
Rule Affected	Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement)
Compliance Deadline	March 29, 2027 (180 calendar days)

Financial Impact Assessment

Transaction Materiality

Metric	Value
Market Capitalization	~$20,000,000 ($0.02B)
Shares Outstanding	14,980,000 shares
Transaction Type	Non-Transactional Corporate Disclosure (Item 3.01)
Dilution Impact	Potential future dilution or capital restructuring (reverse split risk)
Materiality Assessment	Moderate (Operational & Listing Continuity Risk)

Impact Evaluation

• Market Cap Context: Operating at a micro-cap valuation of ~$20M, the company's sub-$1.00 stock price reflects protracted market valuation pressures common in early/commercial clinical-stage biopharma.
• Listing Timeline: The letter imposes no immediate effect on Nasdaq Capital Market listing. DARE has an initial 180-day cure window ending March 29, 2027, requiring a closing bid of at least $1.00 for 10 consecutive business days.
• Potential Remedies: If compliance is not regained by March 29, 2027, the company may qualify for a second 180-day grace period, provided it meets other listing criteria and signals intent to cure through corporate actions such as a reverse stock split.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: While a Nasdaq deficiency notice introduces listing uncertainty and headline risk, the immediate operation of the stock is unaffected. A 180-day cure period provides ample breathing room before forced structural actions.

Volume & Sentiment

• Expected Volume Impact: Modest uptick in turnover driven by algorithmic rebalancing and micro-cap event-driven desks.
• Sentiment Indicator: Bearish to Neutral; retail and institutional participants may price in the friction of a potential reverse stock split.

Additional Context

• Signatory: Sabrina Martucci Johnson, President and Chief Executive Officer.
• Cure Precedents: Biopharma micro-caps routinely navigate minimum bid deficiency periods through clinical catalysts, strategic transactions, or reverse splits as a last resort.